Transitioning from Reusable to Single-Use Ophthalmic Instruments: Practical Considerations for Healthcare Providers
Across NHS trusts and private ophthalmic clinics, procurement and theatre teams are under mounting pressure to review how surgical instruments are sourced, processed, and managed. Sterilisation validation requirements are becoming more rigorous, reprocessing workloads are rising, and the operational costs associated with managing reusable instrument sets are receiving increasing scrutiny. At the same time, single-use ophthalmic instruments have matured significantly as a product category – offering consistent sterility, simplified compliance documentation, and greater predictability in theatre scheduling.
This guide is not an argument for wholesale conversion. It is a structured framework to help procurement managers, theatre managers, and clinical leads evaluate whether a full or partial transition to single-use ophthalmic instruments is appropriate for their organisation – and, if so, how to approach it methodically.
Why organisations are reconsidering reusable instruments
The decision to review reusable instrument strategies rarely stems from a single pressure point. More often, it reflects an accumulation of compliance, operational, and capacity-related challenges that, taken together, make the status quo difficult to sustain.
Regulatory and compliance burden. Reusable medical devices must be reprocessed in line with manufacturer instructions for use (IFU), as set out under ISO 17664-1:2021 and reinforced by NHS Health Technical Memorandum HTM 01-01. The HTM is explicit that responsibility for achieving acceptable standards of decontamination rests with commissioners, individual trusts, and provider organisations. Validation of cleaning and sterilisation processes is not optional – it requires ongoing monitoring, documented protocols, and regular audit.
Traceability requirements. Batch and lot traceability for reusable instruments demands robust tracking systems throughout the entire reprocessing cycle. Any break in that chain carries both clinical and regulatory risk.
Reprocessing capacity constraints. Sterile Services Departments (SSDs) operate under significant throughput pressure. When instrument turnaround is delayed – due to volume, staffing, or equipment downtime – theatre lists are directly affected. HTM 01-01 highlights minimising procedure delays and cancellations linked to instrument availability as a key commissioning objective.
Infection control scrutiny. Residual protein contamination on inadequately cleaned instruments remains a genuine clinical concern, particularly regarding prion risk. The requirement to continuously monitor residual protein on reprocessed instruments adds further resource demand on SSDs.
None of this makes reusable instruments clinically inappropriate. However, it does mean that organisations should periodically reassess whether their current model remains sustainable and compliant.
Financial considerations beyond unit price
A common misconception is that reusable instruments are inherently more cost-effective because the unit cost is spread across multiple uses. Total Cost of Ownership (TCO) analysis often tells a more nuanced story.
The full cost of a reusable instrument includes:
• Reprocessing costs – staff time, water, energy, detergents, and sterilisationconsumables across every cycle
• Logistics to and from the SSD – transport, handling, and administration
• Repair and refurbishment – precision instruments degrade with repeated use and sterilisation
• Loss and damage rates – instruments that are dropped, missing from sets, or condemned add unpredictable costs
• Audit and documentation overhead – compliance administration is not cost-free
Single-use ophthalmic instruments offer a fixed, predictable cost per procedure. That transparency can be particularly valuable for organisations managing high-volume cataract lists or intravitreal injection programmes, where per-case budgeting is important. The trade-off is waste management cost, which should be factored into any honest financial model.
Compliance and risk management implications
One of the most significant practical advantages of single-use ophthalmic instruments is the shift in validation responsibility. With a reusable instrument, the healthcare organisation is responsible for demonstrating that its reprocessing cycle meets the manufacturer’s IFU – every time. With a single-use instrument, sterilisation validation has already been performed by the manufacturer. The device arrives sterile and ready to use, with the compliance burden sitting firmly with the supplier rather than the clinical team.
This does not eliminate documentation requirements entirely – receiving, storage, and traceability records remain necessary – but it substantially reduces the audit burden at the point of use. Batch tracking is simplified. There is no need to manage IFU compliance per instrument type across multiple manufacturers. For organisations facing increasing CQC scrutiny or internal audit pressure, this is a material operational advantage.
Surgitrac’s Quality & Credentials page sets out its ISO 13485:2016 certification, CE marking across its product range, and batch and lot traceability systems – providing the documentary assurance that procurement and compliance teams require when evaluating a supplier.
Operational and theatre efficiency impact
Theatre efficiency is closely tied to instrument availability. Reprocessing delays, incomplete sets, or instruments held at the SSD can push back start times, interrupt lists, and reduce the number of procedures completed in a session.
Single-use ophthalmic instruments remove the reprocessing variable entirely. Pre-sterilised ophthalmic procedure packs – which can include instruments, drapes, swabs, and gallipots assembled in a single sterile wrap – allow theatre teams to work to a predictable “open and use” workflow. There is no pre-operative instrument inspection for damage or degradation. No waiting for sets to return from the SSD. No counting instruments back into trays post-procedure.
This does not mean every procedure is better served by single-use. Complex instrument sets, specialist retractors, and high-value precision instruments may warrant retention as reusable. The operational gains are most pronounced in high-volume, standardised procedures such as cataract surgery and intravitreal injections.
A practical transition checklist for healthcare providers
For organisations considering a partial or full transition to single-use ophthalmic instruments, the following framework may assist planning and internal evaluation.
Strategic Planning
• Have we quantified our current reprocessing costs?
• What proportion of theatre delays are linked to instrument availability?
• Are we facing sterilisation capacity constraints?
• Have we modelled a phased transition rather than full conversion?
Compliance & Governance
• Can we consistently validate reprocessing to manufacturer IFU standards?
• Are audit requirements increasing?
• Do we have full traceability systems for reusable instruments?
• Are infection control teams aligned on risk tolerance?
Financial Modelling
• What is the true Total Cost of Ownership per case?
• How volatile are labour and energy costs?
• Would single-use provide cost transparency per procedure?
• Have we assessed waste management costs?
Clinical Alignment
• Are surgeons open to trialling single-use instruments?
• Have we tested instrument feel and balance?
• Are there procedures where reusable remains preferable?
• Would a hybrid model be appropriate?
Supply & Logistics
• Is there reliable UK-based stock holding?
• Can suppliers provide continuity assurances?
• Do suppliers manufacture directly or source from third parties?
• Can delivery timelines support theatre scheduling?
Implementation Planning
• Will transition occur procedure-by-procedure?
• Have we engaged procurement early?
• Is staff training required?
• Have we evaluated storage and stock management implications?
Hybrid models – a pragmatic approach
A full switch to single-use is not the only option, and for many organisations it may not be the right one. A hybrid model – retaining reusable instruments for complex or infrequently used sets while transitioning high-volume, standardised procedures to single-use – is a practical and increasingly common approach.
Cataract surgery is the most natural starting point for many units. Standardised instrument sets, high procedural volumes, and significant reprocessing workload make cataract-specific procedure packs a logical first conversion. Intravitreal injection programmes, which share similar characteristics, are another area where single-use procedure packs have gained traction.
Instruments that are difficult to clean – those with box joints, serrations, or complex internal channels – are also strong candidates for single-use substitution, given the residual protein monitoring requirements outlined in HTM 01-01.
Common concerns and how to address them
Sustainability. This is a legitimate consideration. Single-use instruments generate plastic waste. However, the environmental comparison with reusable instruments is not straightforward. Reprocessing consumes energy, water, and chemical detergents at scale. Surgitrac publishes a Carbon Reduction Plan and Environmental Policy as part of its commitment to reducing its operational footprint, and is working towards Net Zero by 2045. Organisations should weigh the full lifecycle impact of both models rather than defaulting to assumptions in either direction.
Surgeon preference. Some surgeons have strong preferences based on instrument feel and familiarity. These preferences deserve serious consideration. Trialling single-use instruments on specific procedures before committing to a wider transition is a straightforward way to address this concern with evidence rather than assumption.
Storage space. Single-use instruments require adequate storage capacity. This is a practical constraint that should be factored into planning, particularly for smaller units. However, a supplier with sufficient warehousing can help manage stock and provide instruments as needed, reducing the burden on local storage.
Perceived cost. As discussed above, unit price is not the same as total cost. A structured TCO analysis, developed in collaboration with procurement, provides a far more useful basis for decision-making than headline price comparisons.
Supporting a managed transition
Surgitrac manufactures and supplies a broad range of single-use and reusable ophthalmic instruments, as well as sterile ophthalmic procedure packs, from its UK base in Manchester. The business holds ISO 13485:2016 certification and operates with UK stockholding to support consistent supply to NHS trusts and private clinics. Whether an organisation is considering a partial transition, evaluating procedure packs for specific lists, or reviewing its entire instrument strategy, the team is available to discuss options without a prescriptive approach.
Explore Surgitrac’s range of single-use and reusable ophthalmic instruments, or contact our team to discuss a tailored transition strategy.
